# Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer

> **NCT07716735** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Kidney Carcinoma
- Advanced Renal Cell Carcinoma
- Hereditary Leiomyomatosis and Renal Cell Carcinoma
- Metastatic Kidney Carcinoma
- Metastatic Renal Cell Carcinoma
- Skin Leiomyoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Uterine Corpus Leiomyoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Mercaptopurine
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Skin Biopsy

## Key facts

- **NCT ID:** NCT07716735
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2034-12-01
- **Final completion:** 2035-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-08-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07716735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07716735, "Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07716735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*